Eevia Health (EEVIA.ST) Stock Analysis & AI Equity Report
Eevia Health (EEVIA.ST) overview
Eevia Health (EEVIA.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Eevia Health reported revenue of EUR 1.8m and operating profit of EUR -1.4m; the year-end share price was 0.16 SEK and market capitalisation was N/A. Eevia Health is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Eevia Health's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-04. Data will be refreshed during report generation.
About Eevia Health
Eevia Health Plc develops and manufactures standardized plant-based ingredients for dietary supplements, food and drink, cosmetics, and flavors. Its portfolio is built around polyphenol extracts and side-stream products from wild berries, pine bark, and chaga, produced in Finland using proprietary extraction and purification processes and sold to industrial customers.
Generate the Eevia Health report
Eevia Health is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Eevia Health and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.